A first-in-human Phase 1/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit vaccine (IVX-121) in healthy young and older adults

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in all age groups, with substantial burden in older adults. Here, we report the safety and immunogenicity of IVX-121, an investigational virus-like particle vaccine against RSV. This Phase 1/1b trial (EudraCT num...

Description complète

Détails bibliographiques

Auteurs principaux:	Ilse De Coster, Isabel Leroux-Roels, Kanchanamala Withanage, Leen Suykens, Valentino D’Onofrio, Geert Leroux-Roels, Pierre van Damme, Max Ciarlet, Elizabeth M. Adams, Wasima Rida, Judy Wen, Margaret MacDonald, Jennifer Price, Niranjan Kanesa-thasan
Format:	Artigo
Langue:	Inglês
Publié:	Taylor & Francis Group 2026-12-01
Collection:	Human Vaccines & Immunotherapeutics
Sujets:	IVX-121 respiratory syncytial virus RSV vaccine virus-like particle
Accès en ligne:	https://www.tandfonline.com/doi/10.1080/21645515.2026.2633021
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!